A carregar...
A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial (ADVL1111)
BACKGROUND: The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase I and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tum...
Na minha lista:
| Publicado no: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5657151/ https://ncbi.nlm.nih.gov/pubmed/28449393 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26565 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|